Yang Hui-Hsin, Chang Chia-Wen, Chen Tai-Di
Department of Pharmacy Chang Gung Memorial Hospital, Taoyuan Taoyuan City Taiwan.
Department of Nephrology Chang Gung Memorial Hospital, Linkou Taiwan.
Clin Case Rep. 2023 Mar 7;11(3):e6991. doi: 10.1002/ccr3.6991. eCollection 2023 Mar.
Nivolumab belongs to immune checkpoint inhibitors (ICIs). ICIs-induced kidney injury is rare and acute interstitial nephritis (AIN) is the majority. A 58-year-old woman had gastric cancer treated with nivolumab. Her serum creatinine (Cr) increased to 5.94 mg/dL post 2 cycles of nivolumab and co-administered with acemetacin. A kidney biopsy showed acute tubular injury (ATI). Nivolumab rechallenge was done and Cr worsened again. The lymphocyte transformation test (LTT) indicated a strong positive for nivolumab. Although rare, ATI due to ICIs could not be ruled out, and LTT is a tool to identify the culprit.
纳武利尤单抗属于免疫检查点抑制剂（ICIs）。ICIs 引起的肾损伤较为罕见，其中急性间质性肾炎（AIN）占大多数。一名 58 岁女性患有胃癌，接受纳武利尤单抗治疗。在接受 2 个周期的纳武利尤单抗治疗并同时使用阿西美辛后，她的血清肌酐（Cr）升至 5.94 mg/dL。肾脏活检显示为急性肾小管损伤（ATI）。再次使用纳武利尤单抗后 Cr 再次恶化。淋巴细胞转化试验（LTT）显示对纳武利尤单抗呈强阳性。尽管罕见，但不能排除 ICIs 导致的 ATI，而 LTT 是识别病因的一种工具。
